nach oben

Erschienen in:

01.06.2009 | Original Article

Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients

verfasst von: Tsuguhiko Seo, Atsushi Tatsuguchi, Seiichi Shinji, Masaoki Yonezawa, Keigo Mitsui, Shu Tanaka, Shunji Fujimori, Katya Gudis, Yuh Fukuda, Choitsu Sakamoto

Erschienen in: Virchows Archiv | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to investigate the expression of three prostaglandin E synthase (PGES) isomers in colorectal cancer (CRC) tissue and to evaluate their relationship to clinicopathological factors and patient prognosis. Microsomal PGES (mPGES)-1, mPGES-2, cytosolic PGES (cPGES) and cyclooxygenase (COX)-2 protein expression were analyzed by real-time polymerase chain reaction and Western blot. The localization of each PGES and COX-2 protein was examined by immunohistochemistry in 155 surgical resections and correlated to clinicopathological factors and patient prognosis. mPGES-1 mRNA and protein levels were significantly higher in CRC than in paired normal tissues. mPGES-1 immunoreactivity localized in cancer cells in 43% of cases. mPGES-2 immunoreactivity was significantly more pronounced in cancer cells than in adjacent normal epithelium in 36% of cases. cPGES immunoreactivity was homogeneous in cancer cells and thus determined constitutive. mPGES-1 and mPGES-2 correlated with significantly worse prognosis in stage I–III patients. These results indicate that mPGES-1 and mPGES-2 may each play a role in CRC progression.

Ulrich CM, Bigler J, Potter JD (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6:130–140PubMedCrossRef

Sinicrope FA, Gill S (2004) Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 23:63–75PubMedCrossRef

Kawamori T, Rao CV, Seibert K et al (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58:409–412PubMed

Rahme E, Barkun AN, Toubouti Y et al (2003) The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 125:404–412PubMedCrossRef

Bertagnolli MM, Eagle CJ, Zauber AG et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873–884PubMedCrossRef

Arber N, Eagle CJ, Spicak J et al (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885–895PubMedCrossRef

Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131–2142PubMedCrossRef

Sinicrope FA (2006) Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. Mol Carcinog 45:447–454PubMedCrossRef

Wang D, Dubois RN (2006) Prostaglandins and cancer. Gut 55:115–122PubMedCrossRef

10.

Jakobsson PJ, Thoren S, Morgenstern R et al (1999) Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 96:7220–7225PubMedCrossRef

11.

Tanioka T, Nakatani Y, Semmyo N et al (2000) Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 275:32775–32782PubMedCrossRef

12.

Tanikawa N, Ohmiya Y, Ohkubo H et al (2002) Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochem Biophys Res Commun 291:884–889PubMedCrossRef

13.

Han R, Tsui S, Smith TJ (2002) Up-regulation of prostaglandin E2 synthesis by interleukin-1beta in human orbital fibroblasts involves coordinate induction of prostaglandin-endoperoxide H synthase-2 and glutathione-dependent prostaglandin E2 synthase expression. J Biol Chem 277:16355–16364PubMedCrossRef

14.

Murakami M, Naraba H, Tanioka T et al (2000) Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275:32783–32792PubMedCrossRef

15.

Murakami M, Nakashima K, Kamei D et al (2003) Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 278:37937–37947PubMedCrossRef

16.

Yoshimatsu K, Golijanin D, Paty PB et al (2001) Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 7:3971–3976PubMed

17.

van Rees BP, Sabula A, Thorne S et al (2003) Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines. Int J Cancer 107:551–556PubMedCrossRef

18.

Mehrotra S, Morimiya A, Agarwal B et al (2006) Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy. J Pathol 208:356–363PubMedCrossRef

19.

Rask K, Zhu Y, Wang W et al (2006) Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer 5:62PubMedCrossRef

20.

Gudis K, Tatsuguchi A, Wada K et al (2007) Clinical significance of prostaglandin E synthase expression in gastric cancer tissue. Hum Pathol 38:1826–1835PubMedCrossRef

21.

Nakanishi M, Montrose DC, Clark P et al (2008) Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res 68:3251–3259PubMedCrossRef

22.

Kamei D, Murakami M, Nakatani Y et al (2003) Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem 278:19396–19405PubMedCrossRef

23.

Gudis K, Tatsuguchi A, Wada K et al (2005) Microsomal prostaglandin E synthase (mPGES)-1, mPGES-2 and cytosolic PGES expression in human gastritis and gastric ulcer tissue. Lab Invest 85:225–236PubMedCrossRef

24.

Guo H, Tatsuguchi A, Shinji S et al (2006) Cyclooxygenase-2 expression correlates with membrane-type-1 matrix metalloproteinase expression in colorectal cancer tissue. Dis Colon Rectum 49:1184–1192PubMedCrossRef

25.

Tatsuguchi A, Kishida T, Fujimori S et al (2006) Differential expression of cyclo-oxygenase-2 and nuclear beta-catenin in colorectal cancer tissue. Aliment Pharmacol Ther 24(Suppl 4):153–159

26.

Stichtenoth DO, Thoren S, Bian H et al (2001) Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J Immunol 167:469–474PubMed

27.

Fux R, Schwab M, Thon KP et al (2005) Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res 11:4754–4760PubMedCrossRef

28.

Tsujii M, Kawano S, Tsuji S et al (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705–716PubMedCrossRef

29.

Tatsuguchi A, Matsui K, Shinji Y et al (2004) Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Hum Pathol 35:488–495PubMedCrossRef

30.

Tanaka S, Tatsuguchi A, Futagami S et al (2006) Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma. Gut 55:54–61PubMedCrossRef

31.

Kudo I, Murakami M (2005) Prostaglandin e synthase, a terminal enzyme for prostaglandin E2 biosynthesis. J Biochem Mol Biol 38:633–638PubMed

32.

Watanabe K, Ohkubo H, Niwa H et al (2003) Essential 110Cys in active site of membrane-associated prostaglandin E synthase-2. Biochem Biophys Res Commun 306:577–581PubMedCrossRef

33.

Hu J, Meng Q, Roy SK et al (2002) A Novel Transactivating Factor That Regulates Interferon-gamma-dependent Gene Expression. J Biol Chem 277:30253–30263PubMedCrossRef

34.

Wright KL, Weaver SA, Patel K et al (2004) Differential regulation of prostaglandin E biosynthesis by interferon-gamma in colonic epithelial cells. Br J Pharmacol 141:1091–1097PubMedCrossRef

35.

Bresalier RS, Sandler RS, Quan H et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–1102PubMedCrossRef

36.

Cheng Y, Wang M, Yu Y et al (2006) Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116:1391–1399PubMedCrossRef

37.

Elander N, Ungerbäck J, Olsson H et al (2008) Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APC(Min/+) mice. Biochem Biophys Res Commun 372:249–253PubMedCrossRef

Titel: Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients
verfasst von: Tsuguhiko Seo
Atsushi Tatsuguchi
Seiichi Shinji
Masaoki Yonezawa
Keigo Mitsui
Shu Tanaka
Shunji Fujimori
Katya Gudis
Yuh Fukuda
Choitsu Sakamoto
Publikationsdatum: 01.06.2009
Verlag: Springer-Verlag
Erschienen in: Virchows Archiv / Ausgabe 6/2009
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-009-0777-z

Neu im Fachgebiet Pathologie

Open Access 15.04.2024 | Biomarker | Schwerpunkt: Next Generation Pathology

Springer Medizin

Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2009

Sampling lobular neoplasia of the breast: underestimation despite technical success?

Primary thyroid and thyroid-like follicular carcinoma of the kidney versus solitary metastatic carcinoma of the thyroid: a vexing issue

Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy

Difference between RAT and clear cell papillary renal cell carcinoma/clear renal cell carcinoma

Extraconal orbital tumors in children—a spectrum

Altered expression of CD44 and DKK1 in the progression of Barrett’s esophagus to esophageal adenocarcinoma

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie